Annovis Bio (ANVS) news
Recent news
Annovis Bio - Open-label Alzheimer's study for buntanetap to begin October 2026
Annovis Bio, Inc. (NYSE: ANVS) announced that its open-label extension (OLE) study for Alzheimer’s disease (AD) patients will begin in October 2026 . This study will allow participants who have completed the pivotal Phase 3 trial of buntanetap to continue receiving the investigational therapy. The…
AInvest Wire · 6d agoAnnovis Bio - Phase 3 Alzheimer's disease trial fully enrolled; top-line data and submissions expected in 2027
Annovis Bio, Inc. (NYSE: ANVS) has announced the full enrollment of its pivotal Phase 3 clinical trial (NCT06709014) evaluating buntanetap for early-stage Alzheimer’s disease (AD). The trial, which exceeded initial enrollment projections, has enrolled 850 patients across 83 clinical sites in the…
AInvest Wire · 6d agoAnnovis Bio - preparing for two NDA submissions following data readouts
AInvest Wire · Jul 7, 2026Annovis prices $15M offering of stock and accompanying warrants
AInvest Wire · May 20, 2026Annovis starts offering of stock and accompanying warrants
Annovis Bio, Inc. (NYSE: ANVS) has announced the pricing of an underwritten public offering of 5,263,156 shares of its common stock, together with accompanying warrants to purchase up to the same number of shares of common stock. The combined offering price for each share and warrant is $1.90. Each…
AInvest Wire · May 19, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.